Promotion and the Rational Use of Medicines in a Global Market. Health Projects for Latvia November 2012

Similar documents
S P E C I A L I S T A N D M A S T E R S T U D I E S

Paris, 15 June 2013 Response to a public consultation

From I.P to N.P A Call for a New Paradigm. Dr A. Schwartz

TACD RECOMMENDATIONS ON HEALTH CARE AND INTELLECTUAL PROPERTY AND EUROPEAN COMMISSION SERVICES RESPONSES

University of Cincinnati College of Medicine

Global Policy on Interactions with Healthcare Professionals

For a Healthier America: Reducing Prescription Drug Misuse and Abuse

The EFPIA Disclosure Code: Your Questions Answered

This is meant to be a narrative rather than a critical summary I have a lot of questions about the proposal but I will look into these separately.

Singapore Clinical Trials Register. Foo Yang Tong Director Clinical Trials Branch Health Products Regulation Group HEALTH SCIENCES AUTHORITY

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

TERMS OF REFERENCE (TORS) FOR CONSULTANCY FOR ASSESSMENT OF THE PHARMACEUTICAL MANAGEMENT SYSTEM AND TRAINING

Board Statute Regarding Gifts to Physicians

The College of Family Physicians of Canada. Position Statement Prescribing Rights for Health Professionals

PCNE Classification for Drug related problems

List of Guiding Principles Promoting Good Governance in the Pharmaceutical Sector 1

Institute for Safe Medication Practices

Third EU Health Programme

MA Healthcare Reform Legislation: Assessment of Massachusetts Department of Public Health Regulations

10/31/2014. Medication Adherence: Development of an EMR tool to monitor oral medication compliance. Conflict of Interest Disclosures.

Amgen GLOBAL CORPORATE COMPLIANCE POLICY

Principles Governing Academy Relationships with External Sources of Support

Introduction to Medication Management Systems, Inc. Comprehensive Medication Therapy Management Solutions

Polypill uptake in India & Universal Health Care Programs

POSITION PAPER. Promotion of off-label use of medicines by European healthcare bodies in indications where authorised medicines are available

West Midlands Centre for ADRs. Jeffrey Aronson. Robin Ferner. Side Effects of Drugs Annuals. Editor Meyler s Side Effects of Drugs

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD

Conduct of clinical Trials Communication of

Ethical Issues Surrounding the Conduct of Pediatric Clinical Studies

STONY BROOK UNIVERSITY HOSPITAL GRADUATE MEDICAL EDUCATION POLICIES AND PROCEDURES PHARMACEUTICAL VENDOR/CORPORATION RELATIONSHIPS

REFERENCE CODE GDHC269DFR PUBLICATION DATE JULY 2013 PREMARIN (POSTMENOPAUSAL VAGINAL ATROPHY) - FORECAST AND MARKET ANALYSIS TO 2022

Formulary Management

REGULATIONS FOR THE POSTGRADUATE CERTIFICATE IN PUBLIC HEALTH (PCPH) (Subject to approval)

Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998

healthcare associated infection 1.2

Classification for Drug related problems

How To Be A Nurse Practitioner

Clinical research trials and insurance

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd

HUMAN MEDICINES. Generic medicines. Our advice

History and Principles of Good Clinical Practice

Rational Drug Use: Prescribing, Dispensing, Dispensing, Counseling and Adherence in ART Programs. Supported by USAID

Operational Definition for Evidence-Based Practices Addictions and Mental Health Division September 11, 2007

The Patient-Centered Medical Home How Does Managed Care Pharmacy Add Value?

Communicating uncertainty about benefits and

Policy for Managing Private Healthcare Industry* (PHCI) Interactions at the UNM HSC Clinical Care and Educational Missions**

Professional Standards and Guidelines

EFPIA position on Clinical Trials Regulation trialogue

Join our scientific talent community

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:

c. determine the factors that will facilitate/limit physician utilization of pharmacists for medication management services.

Advancing research: a physician s guide to clinical trials

Chander Sehgal, MD, MBA Director, Common Drug Review (CDR) Taipei, Taiwan July 23 26, 2012

PHARMACEUTICAL MANAGEMENT PROCEDURES

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

Xarelto (Atrial Fibrillation) - Analysis and Forecasts to 2022

Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada

Health Policy 201 drugs. Ellen Andrews, PhD Fall 2011

Insurance and compensation in the event of injury in Phase I clinical trials

Expectations for HCV Therapy with Small Molecules: An Activist Perspective

Transatlantic Trade and Investment Partnership (TTIP): Towards better health outcomes for patients and economic growth

The Role of Regional Medical Advisor (RMA)-Field Medical. Dr. Aju Abraham Varghese Pfizer India. Feb 22 nd 2014

PRIORITY RESEARCH TOPICS

Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report

Medicines Benefits in Korea

Industry Support of Medical Education and CPD. Industry Support of Medical Education and Continuous Professional Development.

Orphan drugs: rising to the challenge to ensure a better future for 30 million patients in Europe

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

OPTIMISING PATIENT OUTCOMES THROUGH PHYSICIAN EDUCATION

REMINDER-BASED OR ON-DEMAND DECISION SUPPORT SYSTEMS : A PRELIMINARY STUDY IN PRIMARY CARE WITH THE MANAGEMENT OF HYPERTENSION

Driving improved access to treatment via Europe and through national MS Societies

Our Mission. How does Colorado Medicaid Work? Objectives

How GSK supports independent medical education

A new value-based approach to the pricing of branded medicines. Submission from the MS Society March 2011

Pharmacists improving care in care homes

Substance Use: Addressing Addiction and Emerging Issues

A Primer: Solving the Unique Problems of Orphan Drug Communications Programs

Managing Medicines Access Programs. Guiding principles for the governance of Medicines Access Programs in Australian hospitals

How To Improve Safety

National Centre for Pharmacoeconomics. Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations

INVITATION LETTER ASSIGNMENT TITLE: INDIVIDUAL CONSULTANCY SERVICES RELATED TO THE TRAINING ON ADVANCED GCP TRAINING FOR RBC/MRC.

GENERAL PRACTICE BASED PHARMACIST

Bayer HealthCare s Comprehensive Compliance Program Pursuant to California Health and Safety Code

Market Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform

Hospital pharmacists as part of the Drug & Therapeutics Committee I

Medication or. treatment of depression and. Dr. Declan Aherne. Psychotherapist

A Comprehensive Look at Drug Policies: The Case of Medical Marijuana


Collaborative Drug Therapy

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Quick Tips: Identification and Management of Conflicts of Interest and Transparency to Learners 1

Pharmacy and Therapeutics Committee Policies and Procedures

Marshall University Joan C. Edwards School of Medicine Conflict of Interest Policy. Introduction

John C. Horton President, LegitScript

Evidence-based Health Policies for Medical Devices and Diagnostics in Asia. Outline of Presentation

Code of Professional Conduct and Ethics for Registered Nurses and Registered Midwives

THEME: PROMOTING GOOD PRACTICES IN DRUG POLICY DEVELOPMENT AND IMPLEMENTATION

Opioids and the Injured Worker Tools for Successful Outcomes

Transcription:

Promotion and the Rational Use of Medicines in a Global Market Health Projects for Latvia November 2012 Tim Reed Health Action International Amsterdam

Acknowledgements: Renée Vasbinder, HAI Global Bobbi Klettke, HAI Global Barbara Mintzes, HAI Member Financial disclosure: No pharmaceutical or advertising industry funding Funding for my position: DFID, UK; DG Sanco, EU

Talk Outline Heath Action International (HAI) Interests in the Medicines Market Promotions Imperative Impact of Promotion Promotion and Rational Use

HAI Constitution: Article 2.1 a. to promote rational and economic medicines policy, therapy and use in high, middle and low income countries b. to work towards global justice in health by increasing access to essential medicines and improving the rational use of medicines

HAI Mission statement: Health Action International (HAI) is an independent, global network working to increase access to essential medicines and improve the rational use of medicines through research excellence and evidencebased advocacy.

The HAI Global Network Health Action International (HAI) is an independent global network, working to increase access to essential medicines and improve the rational use of medicines through research excellence and evidence-based advocacy

Interests and the Political Landscape Promotion and its Regulation intervention in an imperfect market that affect public health interests All interests are affected Pharmaceutical Industry Healthcare Professionals Government Patients Consumer Civil Society

Indentifying Conflict of Interest an inherent conflict of interest between the legitimate business goals of manufacturers and the social, medical and economic needs of providers and the public to select and use drugs in the most rational way. World Health Organization, Regional Office for Europe, 1993

The Promotion Imperative Accountability to Share Holders = to make money Poor Innovation = not much therapeutic advantage Me-Too Medicines = more of the same Disease Mongering = new non-diseases Incentivised R&D Modelling = markets not needs

The Promotion Imperative: Innovation Ratings of 961 new drugs and indications in France, 1999 to 2008 La Revue Prescrire

The Promotion Imperative: Registration & Me-Too medicines No therapeutic innovation Placebo Trials: Requirement to demonstrate efficacy against placebo (only) Me-Too medicines

The Promotion Imperative: R&D Modelling Innovation rewarded with a patent Market Monopoly Encourages promotion (removes market forces) Cost of medicines linked to the cost of R&D No R&D into diseases that disproportionately affect the poor

Does pharmaceutical promotion affect prescribing: Question One. How much influence do sales representatives have on your prescribing? A lot 1% A little 38% None 61% n=102 internal medicine residents Am J Med 2001; 110:551

Does pharmaceutical promotion affect prescribing: Question Two. How much influence do sales representatives have on other physicians' prescribing? None 16% A lot 51% A little 33% n=102 internal medicine residents n=102 internal medicine residents Am J Med 2001; 110:551 Am J Med 2001; 110:551

Gagnon and Lexchin. Cost of pushing pills. PLoS Med 2008 e1 Gagnon and Lexchin. Cost of pushing pills. PLoS Med 2008 e1

EFFECTS OF CME ON VOLUME OF PRESCRIBING Prescribing at major medical institutions Orlowski et al. Chest 1992

Tying it together: Rational Use Essential Medicines Essential medicines are those that satisfy the priority health care needs of the population selected with due regard to disease prevalence, evidence on efficacy and safety, and comparative cost-effectiveness Rational Use of Medicines Patients receive medications appropriate to their clinical needs, in doses that meet their own individual requirements, for an adequate period of time, and at the lowest cost to them and their community." (WHO, 1985). Irrational Use of Medicines Patients receive the wrong medications inappropriate to their clinical needs, in doses that do not meet their own individual requirements, for an inadequate period of time, and at an often unaffordable cost to n=102 internal medicine residents Am J Med 2001; 110:551 them and their community."

Further Information www.haiglobal.org links to other sites in the network, promotions manual, methodology for measuring promotion enforcement, MeTA, Price and Availability methodology www.politicsofmedicines.org Unique encyclopaedia of the politics of medicine, accessible essays that will grow and change with time n=102 internal medicine residents Am J Med 2001; 110:551